| 1. |
Sabatini DM，Erdjument-Bromage H，Lui M，et al.RAFT1：a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.Cell，1994，78：35-43.
|
| 2. |
Brown EJ，Albers MW，Shin TB，et al.A mammalian protein targeted by G1-arresting rapamycin-receptor complex.Nature，1994，369：756-758.
|
| 3. |
Balsara BR，Pei J，Mitsuuchi Y，et al.Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.Carcinogenesis，2004，25：2053-2059.
|
| 4. |
Herberger B，Puhalla H，Lehnert M，et al，Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma.Clin Cancer Res，2007，13：4795-4799.
|
| 5. |
Gera JF，Mellinghoff IK，Shi Y，et al.AKT activity determines sensitivity to mammalian target of rapamycin（mTOR） inhibitors by regulating cyclin D1 and c-myc expression.J Biol Chem，2004，279：2737-2746.
|
| 6. |
Bjornsti MA，Houghton PJ.The TOR pathway：a target for cancer therapy.Nat Rev Cancer，2004，4：335-348.
|
| 7. |
Nave BT，Ouwens M，Withers DJ，et al.Mammalian target of rapamycin is a direct target for protein kinase B：identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.Biochem J，1999，344：427-431.
|
| 8. |
Sekulic A，Hudson CC，Homme JL，et al.A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.Cancer Res，2000，60：3504-3513.
|
| 9. |
Scott PH，Lawrence JC Jr.Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3–L1 adipocytes.J Biol Chem，1998，273：34496-34501.
|
| 10. |
Reynolds TH 4th，Bodine SC，Lawrence JC Jr.Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load.J Biol Chem，2002，277：17657-17662.
|
| 11. |
Sahin F，Kannangai R，Adegbola O，et al.mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms.Clin Cancer Res，2004，10：8421-8425.
|
| 12. |
Zhou X，Tan M，Stone Hawthorne V，et al.Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers.Clin Cancer Res，2004，10：6779-6788.
|
| 13. |
Faried LS，Faried A，Kanuma T，et al.Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy.Oncol Rep，2006，16：57-63.
|
| 14. |
Kremer CL，Klein RR，Mendelson J，et al.Expression of mTOR Signaling PathwayMarkers in Prostate Cancer Progression.Prostate，2006，66：1203-1212.
|
| 15. |
Sieghart W，Fuereder T，Schmid K，et al.Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.Transplantation，2007，83：425-432.
|
| 16. |
Atkins MB，Hidalgo M，Stadler WM，et al.Randomized phase II study of multiple dose levels of CCI-779，a novel mammalian target of rapamycin kinase inhibitor，in patients with advanced refractory renal cell carcinoma.J Clin Oncol，2004，22：909-918.
|
| 17. |
Witzig TE，Geyer SM，Ghobrial I，et al.Phase II trial of single-agent temsirolimus（CCI-779） for relapsed mantle cell lymphoma.J Clin Oncol，2005，23：5347-5356.
|
| 18. |
Galanis E，Buckner JC，Maurer MJ，et al.Phase II trial of temsirolimus（CCI-779） in recurrent glioblastoma multiforme：a North Central Cancer Treatment Group Study.J Clin On col，2005，23：5294-5304.
|
| 19. |
Chan S，Scheulen ME，Johnston S，et al.Phase II study of temsirolimus（CCI-779），a novel inhibitor of mTOR，in heavily pretreated patients with locally advanced or metastatic breast cancer.J Clin Oncol，2005，23：5314-5322.
|
